scispace - formally typeset
Search or ask a question
Topic

Psychotropic drug

About: Psychotropic drug is a research topic. Over the lifetime, 2309 publications have been published within this topic receiving 54070 citations.


Papers
More filters
Journal Article
TL;DR: More research is still needed to identify patients at risk of polypharmacy in psychiatric patients living in an area with very limited mental health resources in order to develop interventions that minimize the risks associated to this treatment alternative.
Abstract: INTRODUCTION Polypharmacy with psychoactive drugs is an increasingly common and debatable contemporary practice in clinical psychiatry more probably based on experience than evidence. The objective of this study was to evaluate the prevalence and estimators of polypharmacy in psychiatric patients living in an area with very limited mental health resources. METHOD All patients (n = 352) with mental disorders receiving psychotropic medication living in La Gomera were studied through an audit of case records and a second phase confirmation strategy through personal interviews. RESULTS The mean number of psychoactive drugs prescribed was 2.22 +/- 0.70 (range: 1-6). The rate of polypharmacy was 67 %, with 34.1 % of patients receiving two drugs, 20.5 % receiving three drugs and 12.5 % of the patients receiving four or more psychotropic drugs at the same time. Multiple regression analysis shows that none of the variables considered (age, sex, marital status, educational level, work activity and diagnosis) had predictive value in regards to the number of psychotropic drug used. Benzodiazepines were the most prevalent drugs in single drug therapy, while antidepressants and antipsychotics were the most used in combination with other treatment. A questionably very high degree of same-class polypharmacy was observed, while multiclass, adjunctive and augmentation polypharmacy seems to be more appropriate. CONCLUSION The psychiatric clinical practice needs to develop indicators for an appropriate polypharmacy of mental disorders. More research is still needed to identify patients at risk of polypharmacy in order to develop interventions that minimize the risks associated to this treatment alternative.

5 citations

Journal ArticleDOI
TL;DR: The solid state structure of the hydrofumarate salt of 5,5-dimethyl-10-(4-methylpiperazinyl)-1O,11-dihydro-5 H -dibenzo[ b, f ]silepin (II), a silicon analog of perathiepin (I) in which divalent sulfur is replaced by the (CH 3 ) 2 Si moiety, has been determined by X-ray diffraction methods as mentioned in this paper.

5 citations

Journal ArticleDOI
TL;DR: Present researches focus on the design of therapeutical molecules targeting the CB2 receptors, and thus avoiding central side effects and therefore psychotropic effects caused by the CB1 receptor.
Abstract: Originally used in Asia for the treatment of pain, spasms, nausea and insomnia, marijuana is the most consumed psychotropic drug worldwide. The interest of medical cannabis has been reconsidered recently, leading to many scientific researches and commercialization of these drugs. Natural and synthetic cannabinoids display beneficial antiemetic, anti-inflammatory and analgesic effects in numerous diseases, however accompanied with undesirable effects due to the CB1 receptor. Present researches focus on the design of therapeutical molecules targeting the CB2 receptors, and thus avoiding central side effects and therefore psychotropic effects caused by the CB1 receptor.

5 citations

Journal Article
TL;DR: Since the inception of the restructured psychotropic drug review service, psychotropic medication dosages have decreased at a projected annual rate of 17% and there have been no significant withdrawal reactions.
Abstract: A redesigned psychotropic drug review service was needed for our 650-bed intermediate care facility for the mentally retarded (ICF/MR). A committee consisting of a client's rights monitor, pharmacist, and psychologist prepared the necessary policy and procedure as well as data collection sheets. Meetings are now conducted in a semiformal fashion, with each discipline contributing in tis area of expertise. Since the inception of the restructured psychotropic drug review service, psychotropic medication dosages (neuroleptic agents only) have decreased at a projected annual rate of 17% and there have been no significant withdrawal reactions. This dosage decrease has saved the institution approximately $2800 to $3200 in medication costs after a 10-month period.

5 citations

Journal Article
TL;DR: The Goodwin data may not provide the definitive answer about lithium compared with other mood stabilizers in reducing mortality, but it does potentially raise the bar in setting standards for outcome in treatment trials involving bipolar disorder.
Abstract: In a recent retrospective cohort study, Goodwin et al1 reported that the risks of suicide attempts and of mortality associated with suicide were significantly lower for patients with bipolar disorder treated with lithium as compared with divalproex sodium Specifically, they showed that death due to suicide was almost 3 times less likely and suicide attempts almost 2 times less likely when patients with bipolar disorder were treated with lithium as compared with divalproex Their data on carbamazepine were consistent with those for divalproex, although their findings were of a preliminary nature In an interview associated with publication of this report, Dr Goodwin, a pre-eminent scholar and author in the field of bipolar disorder, remarked that his study was the first to demonstrate that a psychotropic drug “saved lives” This is an extraordinary statement considering that it is almost 50 years since the modern era of psychopharmacology began with the introduction of chlorpromazine, and more than 30 years since the introduction of lithium as the first treatment for bipolar disorder The Goodwin study is not the first to note the potential antisuicide effect of lithium Other studies have noted and documented this, and there has been discussion about whether lithium may have a specific beneficial effect on propensity to suicide, independent of its mood-stabilizing effects2 Notwithstanding the cautions about the methodology employed in the study conducted by Goodwin et al, it is the first to demonstrate convincingly an advantage of lithium over divalproex and, consistent with earlier studies,3 a potential advantage of lithium over carbamazepine in antisuicide effects It should also be noted that the Goodwin study is the first to compare the effects of 2 treatments; earlier studies used no treatment as the comparison group2 The clinician's choice of pharmacologic treatment for bipolar disorder involves an implicit cost–benefit calculation for each option available To date, for a variety of reasons, divalproex has superseded lithium as the first choice for the acute and prophylactic treatment of bipolar disorder Lithium has generally been relegated from a first-line to an alternative treatment Thus, the Goodwin study and Goodwin's subsequent comments give us pause Reduced mortality or “saving lives” has never been an expectation imposed on psychotropic agents, in general, or on treatments for bipolar disorder in particular The Goodwin data may not provide the definitive answer about lithium compared with other mood stabilizers in reducing mortality, but it does potentially raise the bar in setting standards for outcome in treatment trials involving bipolar disorder Lithium does generally have a less favourable side-effect profile than other treatments for bipolar disorder, particularly divalproex sodium, but if it indeed uniquely reduces long-term mortality, its restoration to first-line treatment for bipolar disorder requires serious consideration Suicidal behaviour is a serious consequence of mood disorders, both bipolar and unipolar In general, patients with mood disorders have a risk of death by suicide that is 9–20 times greater than that of the general population As mood disorders are chronic and recurrent, mortality rates should be a key efficacy measure in treatment studies, as is the case in all other branches of medicine where diseases have high mortality rates Psychiatry should demand no less All treatments for bipolar disorder should be rigorously evaluated for their potential antisuicide effects This applies also to the antipsychotic drugs that are being used more commonly for acute and prophylactic treatment of bipolar disorder, and to clozapine, which has documented antisuicide effects in patients with schizophrenia4 A voluminous literature documents the acute antidepressant efficacy of various agents in the treatment of unipolar depression in the last 50 years, and in particular in the last 20 years since the evaluation and introduction of new-generation antidepressants There is a less extensive literature on the long-term efficacy of antidepressants, and very little attention has been paid to a potential reduction in mortality as an outcome measure in treatment studies of unipolar disorder A vigorous debate has arisen, as exemplified by Healy and Whitaker5 and Lapierre6 in this journal, about whether selective serotonin reuptake inhibitors may enhance the risk of suicide While not diminishing the importance of that debate, the opposite issue should also be addressed The obvious question for future research is whether antidepressants, in general, and selective serotonin reuptake inhibitors, in particular, reduce mortality from suicide in depressed subjects with unipolar disorder In the last few years, there has been an increasing refinement of the outcome measures for the efficacy of antidepressants Differences between response and remission have rightly received increased attention, and quality of life, as well as symptomatic improvement, has been included as a key outcome measure The Goodwin study suggests that raising the bar and including reduced mortality may be necessary in order to truly evaluate the utility and importance of antidepressants Unipolar disorder and bipolar disorder are extraordinarily disabling illnesses that have very high mortality rates As in any other branch of medicine, serious psychiatric illnesses that cause high mortality should have treatments available that both reduce suffering and increase survival Rigorous evaluation of all of these dimensions of outcome will not only serve our discipline well but will also be of great value and benefit to our patients Goodwin's study is an important step along this path

5 citations


Network Information
Related Topics (5)
Schizophrenia
38.2K papers, 1.6M citations
86% related
Anxiety disorder
17.6K papers, 1.3M citations
86% related
Comorbidity
26.8K papers, 1.4M citations
82% related
Anxiety
141.1K papers, 4.7M citations
81% related
Mental health
183.7K papers, 4.3M citations
81% related
Performance
Metrics
No. of papers in the topic in previous years
YearPapers
202332
202268
202175
202058
201960
201876